Research programme: antibody-drug conjugates - ImClone/Seattle Genetics

Drug Profile

Research programme: antibody-drug conjugates - ImClone/Seattle Genetics

Alternative Names: Antibody-drug conjugates research programme - ImClone/Seattle Genetics; EB10-MMAF

Latest Information Update: 09 Apr 2009

Price : $50

At a glance

  • Originator ImClone Systems; Seattle Genetics
  • Class Auristatins; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 20 Oct 2004 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top